The Non-Muscle Invasive Bladder Cancer therapeutics market is anticipated to evolve immensely in the coming years owing to the launch of novel drugs, the rise in the number of cases, and improved diagnosis methodologies.
The high-grade NMIBC pipeline possesses potential drugs in mid and late-stage developments to be launched in the near future. The major key players include Urogen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, and others that hold the potential to create a significant positive shift in NMIBC in the market size and the treatment scenario.
“Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Muscle Invasive Bladder Cancer Market.
The Non-Muscle Invasive Bladder Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Non-Muscle Invasive Bladder Cancer and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Muscle Invasive Bladder Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
Photosensitiser
Apoptosis stimulant
Toll-like receptor 3 agonists
Methionine aminopeptidase 2 inhibitors
Programmed cell death-1 receptor antagonist
Fibroblast growth factor receptor antagonist
Type 1 fibroblast growth factor receptor antagonist
Toll-like receptor 4 agonists
Cell death stimulant
Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Muscle Invasive Bladder Cancer Therapeutic Segment @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight
Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Landscape
Several major pharma and biotech giants are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma is leading the therapeutics market with its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.
In December 2022, US FDA approved ADSTILADRIN (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
The Leading Companies in the Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Market Include:
Abraxis Bioscience
Asieris Pharmaceuticals
AstraZeneca
CG Oncolgy
Hamlet Pharma
ImmunityBio
Incyte Corporation
Janssen Pharmaceuticals
LIPAC Oncology
Prokarium
Rapamycin Holdings
Sasanlimab
Sesen Bio
Taizhou Hanzhong biomedical
Theralase Technologies
Vaxiion Therapeutics
Viralytics
UroGen Pharma
And Many Others
Non-Muscle Invasive Bladder Cancer (NMIBC) Marketed and Emerging Therapies Analyzed in the Report Include:
Adstiladrin(nadofaragenefiradenovec/Syn3): FKD Therapies Oy/Ferring Pharmaceuticals
APL-1202: Asieris Pharmaceuticals
CG0070: CG Oncology
EG-70: enGene
Erdafitinib: Janssen Pharmaceuticals
Keytruda: Merck
N-803 (ALT-803): ImmunityBio/Altor Biosciences
PF-06801591: Pfizer
Sasanlimab (PF-06801591): Pfizer
TARA-002: Protara Therapeutics
TECENTRIQ: Roche
TL-532: Tollys
TLD 1433: Theralase Technologies
UGN-102: UroGen Pharma
VAX 014: Vaxiion Therapeutics
Vicinium: Viventia Bio/Sesen Bio
KEYTRUDA (pembrolizumab): MSD
ADSTILADRIN (nadofaragene firadenovec-vncg): Ferring Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Non-Muscle Invasive Bladder Cancer Current Treatment Patterns
4. Non-Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-Muscle Invasive Bladder Cancer Late Stage Products (Phase-III)
7. Non-Muscle Invasive Bladder Cancer Mid-Stage Products (Phase-II)
8. Non-Muscle Invasive Bladder Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Muscle Invasive Bladder Cancer Discontinued Products
13. Non-Muscle Invasive Bladder Cancer Product Profiles
14. Key Companies in the Non-Muscle Invasive Bladder Cancer Market
15. Key Products in the Non-Muscle Invasive Bladder Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Non-Muscle Invasive Bladder Cancer Unmet Needs
18. Non-Muscle Invasive Bladder Cancer Future Perspectives
19. Non-Muscle Invasive Bladder Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
